HK Stock Movement | LAEKNA-B (02105) Surges Over 6%, Industry Expects LAE002's Peak Sales in China to Reach RMB 2 Billion

Stock News2025-12-01

LAEKNA-B (02105) rose more than 6%, with a gain of 4.92% at the time of writing, trading at HK$17.27 and a turnover of HK$32.15 million. On November 12, LAEKNA announced the licensing of its breast cancer candidate drug LAE002 (afuresertib) to Qilu Pharmaceutical for the Chinese market, with a total deal value of up to RMB 2.045 billion. In addition to an upfront payment, LAEKNA will receive tiered royalties of 10%-20% on sales, ensuring robust funding for future R&D. This transaction marks one of the largest licensing deals in China's biopharma sector this year.

LAE002 is a potent AKT inhibitor. In the HR+/HER2- breast cancer indication, its global development progress is second only to AstraZeneca's Capivasertib. Industry analysts project LAE002's peak sales in China could hit RMB 2 billion, while its global performance may mirror Capivasertib—expected to generate $700-800 million this year, with peak sales potentially exceeding $1-2 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment